Association Between NFKB1 -94ins/delATTG Promoter Polymorphism and Cancer Risk: A Meta-Analysis

REFERENCES

• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539–545.
   PubMed Web of Science ®Google Scholar
• Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004;382:393–409.
   PubMed Web of Science ®Google Scholar
• Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007;22:1387–1398.
   PubMed Web of Science ®Google Scholar
• Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 1986;47:921–928.
   PubMed Web of Science ®Google Scholar
• Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7–17.
   PubMed Web of Science ®Google Scholar
• Le Beau MM, Ito C, Cogswell P, Espinosa R, 3rd.; Fernald AA, Baldwin AS Jr. Chromosomal localization of the genes encoding the p50/p105 subunits of NF-kappa B (NFKB2) and the I kappa B/MAD-3 (NFKBI) inhibitor of NF-kappa B to 4q24 and 14q13, respectively. Genomics 1992;14:529–531.
   PubMed Web of Science ®Google Scholar
• Mathew S, Murty VV, Dalla-Favera R, Chaganti RS. Chromosomal localization of genes encoding the transcription factors, c-rel, NF-kappa Bp50, NF-kappa Bp65, and lyt-10 by fluorescence in situ hybridization. Oncogene 1993;8:191–193.
   PubMed Web of Science ®Google Scholar
• Héron E, Deloukas P, van Loon AP. The complete exon-intron structure of the 156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal transduction. Genomics 1995;30:493–505.
   PubMed Web of Science ®Google Scholar
• Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35–45.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wei Q, Li X, Wang K, Zeng H, Bu H, Li H. A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet 2009;191:73–77.
   PubMed Web of Science ®Google Scholar
• Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery 2009;145:280–285.
   PubMed Web of Science ®Google Scholar
• Tang T, Cui S, Deng X, Gong Z, Jiang G, Wang P, Liao B, Fei Z, Xian S, Zeng D, Li J. Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol 2009;28:1–4.
   Google Scholar
• Burnik FS, Yalcin S. NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009;55:381–385.
   PubMed Web of Science ®Google Scholar
• Lehnerdt GF, Bankfalvi A, Grehl S, Adamzik M, Lang S, Schmid KW, Siffert W, Riemann K. No association of the NF-kappaB1 -94ins/delATTG promoter polymorphism with relapse-free and overall survival in patients with squamous cell carcinomas of the head and neck region. Int J Immunopathol Pharmacol 2008;21:827–832.
   PubMed Web of Science ®Google Scholar
• Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007;45:423–430.
   PubMed Web of Science ®Google Scholar
• Riemann K, Becker L, Struwe H, Nückel H, Dührsen U, Alakus H, Winde G, Neuhäuser M, Rübben H, Schmitz KJ, Wohlschlaeger J, Schmid KW, Siffert W. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006;16:783–788.
   PubMed Web of Science ®Google Scholar
• Zhou B, Rao L, Li Y, Gao L, Wang Y, Chen Y, Xue H, Song Y, Peng Y, Liao M, Zhang L. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 2009;275:72–76.
   PubMed Web of Science ®Google Scholar
• Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, Carstensen J, Zhang ZY, Sun XF. Swedish Low-Risk Colorectal Cancer Study Group. Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 2007;42:1332–1338.
   PubMed Web of Science ®Google Scholar
• Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007;133:859–866.
   PubMed Web of Science ®Google Scholar
• Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2007;243:47–54.
   Web of Science ®Google Scholar
• Egger M, Davey Smith G., Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101–129.
   Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Kang BW, Kim GC, Lee MH, Jeon SW, Chung HY, Yu W. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in patients with gastric cancer. Jpn J Clin Oncol 2009;39:497–501.
   PubMed Web of Science ®Google Scholar
• Rajaraman P, Brenner AV, Butler MA, Wang SS, Pfeiffer RM, Ruder AM, Linet MS, Yeager M, Wang Z, Orr N, Fine HA, Kwon D, Thomas G, Rothman N, Inskip PD, Chanock SJ. Common variation in genes related to innate immunity and risk of adult glioma. Cancer Epidemiol Biomarkers Prev 2009;18:1651–1658.
   PubMed Web of Science ®Google Scholar
• Chang ET, Birmann BM, Kasperzyk JL, Conti DV, Kraft P, Ambinder RF, Zheng T, Mueller NE. Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2009;18:976–986.
   PubMed Web of Science ®Google Scholar
• Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 2009;43:539–545.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG, Habermann TM, Ansell SM, Slager SL. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008;17:3161–3169.
   PubMed Web of Science ®Google Scholar
• Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ, Gonsky R, Cong Y, Vasiliauskas EA, Ippoliti A, Elson CO, Rotter JI, Targan SR. Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation. Gut 2009;58:60–67.
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008;14:1788–1796.
   PubMed Web of Science ®Google Scholar
• Domenyuk VP, Litovkin KV, Verbitskaya TG, Dubinina VG, Bubnov VV. Identification of new DNA markers of endometrial cancer in patients from the Ukrainian population. Exp Oncol 2007;29:152–155.
   PubMedGoogle Scholar
• Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F, Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003;63:3560–3566.
   PubMed Web of Science ®Google Scholar
• Curran JE, Weinstein SR, Griffiths LR. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 2002;188:103–107.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–156.
   PubMed Web of Science ®Google Scholar
• Kuper H, Adami HO, Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med 2000;248:171–183.
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431–436.
   PubMed Web of Science ®Google Scholar
• Karin M, Greten FR. NF-kB: linking inflammation and immunity cancer development and progression. Nat Rev Immunol 2005;5:749–759.
   PubMed Web of Science ®Google Scholar
• Karin M. NF-kB and cancer: mechanisms and targets. Mol Carcinog 2006;45:355–361.
   PubMed Web of Science ®Google Scholar
• Luo JL, Kamata H, Karin M. IKK/NF-kB signaling: balancing life and death—a new approach to cancer therapy. J Clin Invest 2005;115:2625–2632.
   PubMed Web of Science ®Google Scholar
• Tew GW, Lorimer EL, Berg TJ, Zhi H, Li R, Williams CL. SmgGDS regulates cell proliferation, migration, and NF-kappa B transcriptional activity in non-small cell lung carcinoma. J Biol Chem 2008;283:963–976.
   PubMed Web of Science ®Google Scholar
• Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007;26:711–724.
   PubMed Web of Science ®Google Scholar
• Yang J, Pan WH, Clawson GA, Richmond A. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 2007;67:3127–3134.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, Zaniboni A, Catalano V, Quadri A, Zorzi F, Berardi R, Biscotti T, Labianca R, Falcone A, Cascinu S. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007;25:3930–3935.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr., Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB tumor pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115–130.
   PubMed Web of Science ®Google Scholar
• Weichert W, Boehm M, Gekeler V, Bahra M, Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, Niesporek S, Jacob J, Dietel M, Scheidereit C, Kristiansen G. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 2007;97:523–530.
   PubMed Web of Science ®Google Scholar
• Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, Ajani JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 2007;16:1200–1205.
   PubMed Web of Science ®Google Scholar
• Rae C, Langa S, Tucker SJ, MacEwan DJ. Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc Natl Acad Sci USA 2007;104:12790–12795.
   PubMed Web of Science ®Google Scholar
• Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L, Aifantis I. Targeting the NF- kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007;13:70–77.
   PubMed Web of Science ®Google Scholar
• Fabre C, Carvalho G, Tasdemir E, Braun T, Adès L, Grosjean J, Boehrer S, Métivier D, Souquère S, Pierron G, Fenaux P, Kroemer G. NF-kappaB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007;26:4071–4083.
   PubMed Web of Science ®Google Scholar
• Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein–Barrvirus(EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007;81:10029–10036.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang Z, Li T, Tsitsikov EN, Ding HF. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007;110:743–751.
   PubMed Web of Science ®Google Scholar
• Geddes M, Balzi D, Buiatti E, Khlat M, Parkin D. Cancer in Italian migrants. Cancer Causes Control 1991;2:133–140.
   PubMed Web of Science ®Google Scholar
• Iscovich J, Howe GR. Cancer incidence patterns (1972–91) among migrants from the Soviet Union to Israel. Cancer Causes Control 1998;9:29–36.
   PubMed Web of Science ®Google Scholar
• Maskarinec G, Noh JJ. The effect of migration on cancer incidence among Japanese in Hawaii. Ethn Dis 2004;14:431–439.
   PubMed Web of Science ®Google Scholar